首页 > 市场调查报告书 > 製药

癌症生物製剂

市场调查报告书

商品编码

1708115

癌症免疫疗法：科技与全球市场

Cancer Immunotherapy: Technologies and Global Markets

出版日期: 2025年04月17日 | 出版商:

BCC Research | 英文 203 Pages | 订单完成后即时交付

价格

简介目录图表

全球癌症免疫治疗市场规模预计将从 2024 年的 1,442 亿美元增至 2029 年底的 2,472 亿美元，预测期内的复合年增长率为 11.4%。

查核点抑制剂领域预计将从 2024 年的 640 亿美元成长到 2029 年底的 1,078 亿美元，预测期内的复合年增长率为 11.0%。单株抗体领域预计将从 2024 年的 445 亿美元成长到 2029 年底的 804 亿美元，预测期内的复合年增长率为 12.5%。

本报告调查了全球癌症免疫治疗市场，并提供了全面的市场概述、市场影响因素和市场机会的分析、法律制度、新兴技术和技术发展的趋势、市场规模的趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业的概况。

细分市场
全球癌症免疫疗法市场（按治疗类型）
全球市场规模及预测
查核点抑制剂
单株抗体
过继性细胞疗法
细胞激素治疗
癌症疫苗
溶瘤病毒疗法
其他的
全球癌症免疫治疗市场（按癌症类型划分）
全球市场规模及预测
黑色素瘤
白血病
淋巴瘤
骨髓瘤
肺癌
乳癌
大肠直肠癌
其他的
地理分布
全球癌症免疫治疗市场（按地区）
全球市场规模及预测
北美洲
欧洲
亚太地区
其他地区

第七章竞争讯息

概述
竞争格局
企业市场占有率分析

第八章癌症免疫疗法市场的永续性：ESG 视角

ESG：概述
ESG在製药业中的作用
癌症免疫疗法市场的永续性
ESG观点
环境影响
社会影响
管治影响
ESG风险评估
结论

第九章附录

调查方法
简称
来源
公司简介
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.

简介目录图表

Product Code: PHM129C

The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.

The cancer immunotherapy market for checkpoint inhibitors is expected to grow from $64.0 billion in 2024 and is projected to reach $107.8 billion by the end of 2029, at a CAGR of 11.0% during the forecast period of 2024 to 2029.

The cancer immunotherapy market for monoclonal antibodies is expected to grow from $44.5 billion in 2024 and is projected to reach $80.4 billion by the end of 2029, at a CAGR of 12.5% during the forecast period of 2024 to 2029.

Report Scope

This report provides a detailed analysis of the cancer immunotherapy market. It highlights cancer immunotherapy's current and future market potential and analyzes the competitive environment, covering regulatory scenarios, drivers, restraints and opportunities. The report provides market trends in cancer immunotherapy for the forecast period 2024-2029 using data from 2023 and estimates from 2024. It includes projections of compound annual growth rates (CAGRs) through 2029 and provides the market shares of key players in this market.

In this analysis, the cancer immunotherapy market is segmented by therapy types, cancer types and geographic regions. By therapy type, the market is segmented into the following: checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, cytokine therapy, cancer vaccines, oncolytic virus therapy and other immunotherapies. It is segmented by cancer type into melanoma, leukemia, lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer and other cancers.

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The regional analysis includes details about major countries such as the U.S., Canada, Germany, the U.K., Italy, Spain, France, Japan, China, South Korea, Australia and India.

The report aims to:

Analyze therapies and types of cancer.
Analyze global market size and segmentation.
Understand market constraints and drivers.
Provide detailed market forecasts for 2029.
Assess market shares, competitiveness and industry structure.
Identify potential long-term impacts on the cancer immunotherapy market.

Report Includes

75 data tables and 54 additional tables
An analysis of the global cancer immunotherapy market
Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
Estimates of the market size and revenue prospects for the global market, along with a market share analysis by therapy type, cancer type, and region
Coverage of treatments that are in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
Evaluation of recent patent activity and key granted and published patents in the industry
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Profiles of leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., and AstraZeneca

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Key Concepts of Immunotherapy

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Rising Cancer Cases Globally
Robust Approval of Immunotherapy Drugs
Rise in Government Funding and Pharmaceutical R&D Spending
Market Restraints
High Cost of Immunotherapy
Loss of Exclusivity and Genericization
Shortage of Oncology Professionals
Market Opportunities
Technological Advances in Immunotherapy
Potential in Cancer Immunotherapy

Chapter 4 Regulatory Landscape

Overview
U.S.
Europe
Japan

Chapter 5 Emerging Technologies

Overview
Artificial Intelligence (AI)
Emergent Biomarkers
Immunotherapy Pipeline
Patent Analysis
Future Prospects

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Global Market for Cancer Immunotherapy, by Therapy Type
Global Market Size and Forecast
Checkpoint Inhibitors
Monoclonal Antibodies
Adoptive Cell Therapies
Cytokine Therapy
Cancer Vaccines
Oncolytic Virus Therapy
Other Immunotherapies
Global Market for Cancer Immunology, by Cancer Type
Global Market Size and Forecast
Melanoma
Leukemia
Lymphoma
Myeloma
Lung Cancer
Breast Cancer
Colorectal Cancer
Other Cancers
Geographic Breakdown
Global Market for Cancer Immunotherapy, by Region
Global Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Overview
Competitive Landscape
Company Share Analysis

Chapter 8 Sustainability in Cancer Immunotherapy Market: An ESG Perspective

Introduction to ESG
Role of ESG in the Pharma Industry
Sustainability in the Cancer Immunotherapy Market
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Abbreviations
Sources
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.

简介目录图表

List of Tables

Summary Table : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 1 : Porter's Five Forces Analysis: Cancer Immunotherapy Market
Table 2 : Average Price of Immunotherapy
Table 3 : List of Selected Clinical Trial Studies on Immunotherapy, 2025
Table 4 : List of Selected Recent Patents Related to Immunotherapy 2024-2025
Table 5 : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 6 : FDA-Approved Immune Checkpoint Inhibitors 2015-2018
Table 7 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Region, Through 2029
Table 8 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Type, Through 2029
Table 9 : Global Market for Monoclonal Antibodies in Cancer Immunotherapy, by Region, Through 2029
Table 10 : Global Market for Adoptive Cell Therapies in Cancer Immunotherapy, by Region, Through 2029
Table 11 : Global Market for Cytokine Therapy in Cancer Immunotherapy, by Region, Through 2029
Table 12 : Global Market for Cancer Vaccines in Cancer Immunotherapy, by Region, Through 2029
Table 13 : Players Investing in Oncolytic Virology, 2024
Table 14 : Global Market for Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, Through 2029
Table 15 : Global Market for Other Immunotherapies in Cancer Immunotherapy, by Region, Through 2029
Table 16 : Global Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 17 : Global Market for Cancer Immunotherapy in Melanoma, by Region, Through 2029
Table 18 : Global Market for Cancer Immunotherapy in Leukemia, by Region, Through 2029
Table 19 : Global Market for Cancer Immunotherapy in Lymphoma, by Region, Through 2029
Table 20 : Global Market for Cancer Immunotherapy in Myeloma, by Region, Through 2029
Table 21 : Global Market for Cancer Immunotherapy in Lung Cancer, by Region, Through 2029
Table 22 : Global Market for Cancer Immunotherapy in Breast Cancer, by Region, Through 2029
Table 23 : Global Market for Cancer Immunotherapy in Colorectal Cancer, by Region, Through 2029
Table 24 : Global Market for Cancer Immunotherapy in Other Cancers, by Region, Through 2029
Table 25 : Global Market for Cancer Immunotherapy, by Region, Through 2029
Table 26 : North American Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 27 : North American Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 28 : North American Market for Cancer Immunotherapy, by Country, Through 2029
Table 29 : U.S. Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 30 : U.S. Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 31 : Canadian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 32 : Canadian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 33 : Mexican Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 34 : Mexican Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 35 : European Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 36 : European Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 37 : European Market for Cancer Immunotherapy, by Country, Through 2029
Table 38 : German Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 39 : German Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 40 : U.K. Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 41 : U.K. Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 42 : French Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 43 : French Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 44 : Italian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 45 : Italian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 46 : Spanish Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 47 : Spanish Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 48 : Rest of European Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 49 : Rest of European Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 50 : Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 51 : Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 52 : Asia-Pacific Market for Cancer Immunotherapy, by Country, Through 2029
Table 53 : Chinese Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 54 : Chinese Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 55 : Japanese Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 56 : Japanese Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 57 : Indian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 58 : Indian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 59 : Australian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 60 : Australian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 61 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 62 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 63 : Rest of the World Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 64 : Rest of the World Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 65 : Key Focus Areas in ESG Metrics
Table 66 : ESG Rankings for Leading Companies in Cancer Immunotherapy Market, 2024*
Table 67 : Abbreviations Used in this Report.
Table 68 : Report Sources
Table 69 : AbbVie Inc.: Company Snapshot
Table 70 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 71 : AbbVie Inc.: Product Portfolio
Table 72 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 73 : Amgen Inc.: Company Snapshot
Table 74 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 75 : Amgen Inc.: Product Portfolio
Table 76 : Amgen Inc.: News/Key Developments, 2022-2024
Table 77 : AstraZeneca: Company Snapshot
Table 78 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 79 : AstraZeneca: Product Portfolio
Table 80 : AstraZeneca: News/Recent Developments, 2023 and 2024
Table 81 : Bristol-Myers Squibb Co.: Company Snapshot
Table 82 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 83 : Bristol-Myers Squibb Co.: Product Portfolio
Table 84 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 85 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 86 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 87 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 88 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 89 : Gilead Sciences Inc.: Company Snapshot
Table 90 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 91 : Gilead Sciences Inc.: Product Portfolio
Table 92 : Gilead Sciences Inc.: News/Key Developments, 2023 and 2024
Table 93 : Johnson & Johnson Services Inc.: Company Snapshot
Table 94 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 95 : Johnson & Johnson Services Inc.: Product Portfolio
Table 96 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 97 : Lilly: Company Snapshot
Table 98 : Lilly: Financial Performance, FY 2022 and 2023
Table 99 : Lilly: Product Portfolio
Table 100 : Lilly: News/Key Developments, 2022 and 2023
Table 101 : Merck & Co. Inc.: Company Snapshot
Table 102 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 103 : Merck & Co. Inc.: Product Portfolio
Table 104 : Merck & Co. Inc.: News/Key Developments, 2021-2024
Table 105 : Novartis AG: Company Snapshot
Table 106 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 107 : Novartis AG: Product Portfolio
Table 108 : Novartis AG: News/Key Developments, 2022
Table 109 : Pfizer Inc.: Company Snapshot
Table 110 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 111 : Pfizer Inc.: Product Portfolio
Table 112 : Pfizer Inc.: News/Key Developments, 2023 and 2024
Table 113 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 114 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 115 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 116 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 117 : Sanofi: Company Snapshot
Table 118 : Sanofi: Financial Performance, FY 2022 and 2023
Table 119 : Sanofi: Product Portfolio
Table 120 : Sanofi: News/Key Developments, 2022-2024
Table 121 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 122 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 123 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 124 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023
Table 125 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 126 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 127 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 128 : Few Emerging Players in Cancer Immunotherapy Market

List of Figures

Summary Figure : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 1 : Snapshot of Market Dynamics
Figure 2 : Distribution Share of the Most Frequent Cancer Types in Women*, 2022
Figure 3 : Distribution Share of the Most Frequent Cancer Types in Men*, 2022
Figure 4 : Estimated New Cancer Cases and Deaths in the U.S. in 2024
Figure 5 : National Cancer Institute Research Funding, 2012-2019
Figure 6 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
Figure 7 : Immunotherapy-Related Patents and Publications in the U.S. and China
Figure 8 : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 9 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Region, 2023
Figure 10 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Type, 2023
Figure 11 : Global Market Shares of Monoclonal Antibodies in Cancer Immunotherapy, by Region, 2023
Figure 12 : Global Market Shares of Adoptive Cell Therapies in Cancer Immunotherapy, by Region, 2023
Figure 13 : Global Market Shares of Cytokine Therapy in Cancer Immunotherapy, by Region, 2023
Figure 14 : Global Market Shares of Cancer Vaccines in Cancer Immunotherapy, by Region, 2023
Figure 15 : Global Market Shares of Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, 2023
Figure 16 : Global Market Shares of Other Immunotherapies in Cancer Immunotherapy, by Region, 2023
Figure 17 : Global Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 18 : Global Market Shares of Cancer Immunotherapy in Melanoma, by Region, 2023
Figure 19 : Global Market Shares of Cancer Immunotherapy in Leukemia, by Region, 2023
Figure 20 : Global Market Shares of Cancer Immunotherapy in Lymphoma, by Region, 2023
Figure 21 : Global Market Shares of Cancer Immunotherapy in Myeloma, by Region, 2023
Figure 22 : Global Market Shares of Cancer Immunotherapy in Lung Cancer, by Region, 2023
Figure 23 : Global Market Shares of Cancer Immunotherapy in Breast Cancer, by Region, 2023
Figure 24 : Global Market Shares of Cancer Immunotherapy in Colorectal Cancer, by Region, 2023
Figure 25 : Global Market Shares of Cancer Immunotherapy in Other Cancers, by Region, 2023
Figure 26 : Global Market Shares of Cancer Immunotherapy, by Region, 2023
Figure 27 : North American Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 28 : North American Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 29 : North American Market Shares of Cancer Immunotherapy, by Country, 2023
Figure 30 : U.S. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 31 : U.S. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 32 : Canadian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 33 : Canadian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 34 : Mexican Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 35 : Mexican Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 36 : European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 37 : European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 38 : European Market Shares of Cancer Immunotherapy, by Country, 2023
Figure 39 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 40 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 41 : U.K. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 42 : U.K. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 43 : French Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 44 : French Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 45 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 46 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 47 : Spanish Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 48 : Spanish Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 49 : Rest of European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 50 : Rest of European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 51 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 52 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 53 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Country, 2023
Figure 54 : Chinese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 55 : Chinese Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 56 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 57 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 58 : Indian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 59 : Indian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 60 : Australian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 61 : Australian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 62 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 63 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 64 : Rest of the World Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 65 : Rest of the World Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 66 : Top 10 Blockbuster Cancer Immunotherapy Products, by Sales Revenue, 2022-2023
Figure 67 : Global Market Shares of Cancer Immunotherapy, by Company, 2023
Figure 68 : Pillars of ESG
Figure 69 : Advantages of ESG for Companies
Figure 70 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 71 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 72 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 73 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 74 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 75 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 76 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 77 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 78 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 79 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 80 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 81 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 82 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 83 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 84 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 85 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 86 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 87 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 88 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 89 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 90 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 91 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 92 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 93 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 94 : Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 95 : Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 96 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 97 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023
Figure 98 : Teva Pharmaceutical Industries Ltd.: Market Share, by Business Unit, FY 2023
Figure 99 : Teva Pharmaceutical Industries Ltd.: Market Share, by Country/Region, FY 2023

02-2729-4219

+886-2-2729-4219

License/价格

癌症免疫疗法：科技与全球市场

Cancer Immunotherapy: Technologies and Global Markets